Each week we will aim to bring out a concise email that provides 4-5 key pieces of information addressing a specific issue in clinical therapeutics.
This week: High strength insulin 300IU/mL
Wei Jin Wong, Clinical Pharmacist, Ward MM
Recently, a different concentration of insulin glargine has been made available via the PBS.
There are now 2 different strengths available, 100IU/mL (Lantus Solostar©) and 300IU/mL (Toujeo Solostar©).
Toujeo Solostar© is available in 3’s and 5’s
Both by are made and marketed by the same pharmaceutical company – Sanofi.
Images and details taken from
- Study reported a glucose lowering effect that lasted up to 36 hours.
- Similar side effect profile reported with insulin glargine 100units/mL but lower risk of hypoglycemia. Although, the mean age of patients in study group was 57 years of age.
- Some prescribers have been switching from insulin 100IU/mL to 300IU/mL.
- Regular ongoing monitoring is essential as part of pharmacovigilance and reducing medication related harm.
Please consider these issues when preparing or interpreting RMMR reports or education sessions. Contributions of content or suggested topics are welcome and should be sent directly to email@example.com.